| Application of in vivo electroporation to cancer gene therapy. | |
| | |
MedLine Citation:
|
PMID: 12553536 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Much intensive research has gone into the development of safe and efficient methods for the delivery of therapeutic genes. In vivo electroporation is a non-viral delivery protocol in which plasmid DNA solutions are injected into targeted tissues, followed by electric pulses (typically 100 V, 50 ms). In general, in vivo electroporation enhances gene expression in targeted tissues by 2-3 orders of magnitude, as compared to the injection of plasmid DNA solutions without electric pulses, and the tissue damage appears to be minimal. Among the other advantages of this technique are that it can safely be administered repeatedly, and it is simpler and more economical to use than viral vectors, especially in clinical cases. Using this approach, highly efficient gene transfer has already been achieved in muscle and liver as well as in tumors. In fact, gene therapies for cancer utilizing in vivo electroporation have been proved effective in a number of experimental murine tumor models. The therapeutic genes delivered in those cases were diverse including, for example, cytokine genes (IL-12) and cytotoxic genes (TRAIL), making possible a wide range of therapeutic strategies. Moreover, systemic antitumor effects were also observed, suggesting that this approach may be effective for the treatment of metastatic as well as primary tumors. |
| | |
Authors:
|
Takahiko Tamura; Tsuneaki Sakata |
Related Documents
:
|
11829526 - Distinct sets of cellular genes control the expression of transfected, nuclear-localize... 19471876 - Lipid-based emulsion system as non-viral gene carriers. 15139526 - Stabilized nonviral formulations for the delivery of mcp-1 gene into cells of the vascu... 20577786 - Bisethylnorspermine lipopolyamine as potential delivery vector for combination drug/gen... 11682256 - Tetraspan protein cd151: a common target of mood stabilizing drugs? 17948056 - Interaction of shade avoidance and auxin responses: a role for two novel atypical bhlh ... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current gene therapy Volume: 3 ISSN: 1566-5232 ISO Abbreviation: Curr Gene Ther Publication Date: 2003 Feb |
Date Detail:
|
Created Date: 2003-01-29 Completed Date: 2003-07-08 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 101125446 Medline TA: Curr Gene Ther Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 59-64 Citation Subset: IM |
Affiliation:
|
Division of Molecular Regenerative Medicine, Osaka University Graduate School of Medicine, 2-2- B7 Yamadaoka, Suita, Osaka 565-0871, Japan. tamura@onbich.med.osaka-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Apoptosis / genetics Apoptosis Regulatory Proteins Electroporation* Gene Therapy* Interleukin-12 / genetics Membrane Glycoproteins / genetics Mice Muscles / metabolism Neoplasms / genetics*, therapy* TNF-Related Apoptosis-Inducing Ligand Tumor Necrosis Factor-alpha / genetics |
| Chemical | |
Reg. No./Substance:
|
0/Apoptosis Regulatory Proteins; 0/Membrane Glycoproteins; 0/TNF-Related Apoptosis-Inducing Ligand; 0/Tnfsf10 protein, mouse; 0/Tumor Necrosis Factor-alpha; 187348-17-0/Interleukin-12 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Gene therapy for ischemic brain diseases.
Next Document: Diabetes gene therapy: potential and challenges.